By Sabela Ojea
BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity.
The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis.
No transaminase elevations were observed in the tirzepatide only treatment group, the company added.
"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile," Chief Executive Kristen Fortney said.
The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
December 06, 2024 17:15 ET (22:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。